The Short Answer
Incyte stock (INCY) is generally considered halal for Muslim investors. Incyte is a commercial-stage biopharmaceutical company that discovers, develops, and markets therapies in oncology, hematology, and inflammation and autoimmunity, anchored by its JAK-inhibitor franchise. Developing and selling medicines is a permissible activity, so the business-activity screen passes cleanly.
Incyte is notable among biotechs for carrying very little debt and a large cash position, so the leverage screen is comfortably within the threshold. The main purification item is interest income earned on its sizable cash balance.
Sharia Screening Methodology
Islamic scholars use several criteria to screen stocks:
- Business activity screen: Is the company's primary business halal?
- Debt ratio: Total debt / market cap must be under 33%
- Interest income: Interest income / total revenue must be under 5%
- Haram revenue: Revenue from haram sources must be under 5%
- Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)
What Incyte Does
Incyte Corporation (headquartered in Wilmington, Delaware) develops and markets targeted therapies across several areas:
- Oncology and hematology: Its JAK-inhibitor franchise and other cancer therapies.
- Inflammation and autoimmunity: Dermatology and immune-mediated disease treatments.
- Pipeline: A broad research pipeline of small molecules and biologics.
Developing and selling medicines is a permissible activity, so the business-activity screen passes cleanly.
Why It Passes (and What to Check)
1. Permissible Core Business
Incyte's revenue comes from prescription therapies that treat cancer and immune-mediated diseases — a clearly permissible activity. There is no haram revenue line.
2. Low Debt (Strong Screen)
Incyte carries very little debt and a large cash position, so the total-debt-to-market-cap screen is comfortably within the 33% threshold. Still, confirm the debt and receivables ratios against the latest filings.
3. Interest Income (Purify)
Incyte earns interest income on its sizable cash and marketable-securities balance. This should be checked against the 5% threshold and the corresponding portion of returns purified.
Financial Ratios
Based on Incyte's most recent financial statements:
- Total Debt / Market Cap: Very low ✅ (threshold: under 33%)
- Interest Income: On a large cash balance — check and purify ⚠️ (threshold: under 5%)
- Haram Revenue: None ✅ (threshold: under 5%)
- Receivables Ratio: Confirm against filings ⚠️ (threshold: 49–70%, varies by board)
On this basis Incyte screens as halal, with only routine purification of interest income — re-screen periodically as the company grows.
What About Purification?
Purify the portion of returns attributable to interest income earned on Incyte's cash and marketable-securities balance — donating that share of gains to charity.
Verdict from Major Screening Agencies
Incyte stock is generally screened as halal by:
- Zoya App — Compliant, minor purification ✅
- MSCI Islamic criteria — Compliant, low leverage ✅
- Most major Sharia advisory boards — Halal with routine purification ✅
Bottom Line
Incyte (INCY) is generally halal for Muslim investors. The oncology-and-inflammation medicine business is clearly permissible, and the company's low-debt, cash-rich balance sheet makes the leverage screen comfortable. Purify the interest income on cash, confirm the ratios against the latest filings, and re-screen periodically.
Want to check if another stock is halal? Use our free screener.
Open Halal Checker →